Resverlogix Corp. (TSX: RVX) (“Resverlogix”) today announced the publication of two articles in peer-reviewed scientific journals. The first, entitled “Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation” by Fu et al., was published in International Immunopharmacology, and positions apabetalone as a variant-independent therapeutic for post COVID-19 conditions.
International Immunopharmacology Publication Highlights Include:
- SARS-CoV-2, the virus responsible for COVID-19, binds human lung cells via interaction of the viral spike protein and the cell surface receptor called angiotensin converting enzyme 2 (ACE2)
- Apabetalone treatment reduces ACE2 to decrease binding of viral spike proteins including spike proteins from both the Delta and Omicron variants
- Apabetalone treatment also opposes the induction of COVID-related inflammatory mediators, in response to virus-mimicking stimulation of human lung cells
- This research highlights apabetalone’s potential to counter short- and long-term pathologic consequences of the SARS-CoV-2 virus, and positions it as a “variant-independent COVID therapeutic”
The second article, “Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells” by Wasiak et al., was published in Atherosclerosis, and provides new mechanistic insights in to apabetalone’s reduction of cardiovascular risk in obese patients.
Atherosclerosis Publication Highlights Include:
- Apabetalone treatment was evaluated in a diet induced obesity (DIO) mouse model
- Mice on a high-fat diet had greater levels of vascular inflammation markers in the aorta, compared with those on a low-fat diet
- Apabetalone treatment reduced the expression of pro-inflammatory genes in the high-fat diet fed mice compared to untreated controls
- Vascular inflammation is prevalent in obese patients and is a significant driver of negative cardiac events
- This study helps us better understand the mechanism behind the observed cardioprotective benefits of apabetalone in the BETonMACE clinical trial
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Finally, Resverlogix announced today its participation in the upcoming scientific conference hosted by the American College of Cardiology and the World Heart Federation (ACC.23/WCC) in New Orleans, LA. A poster, entitled “Epigenetic BET Reader Inhibitor Apabetalone / RVX-208 Counters Profibrotic and Contractile Activity of Cardiac Fibroblast with Potential Benefit for Heart Failure”, will be presented by Chief Scientific Officer, Dr. Ewelina Kulikowski, on Sunday March 5th, 2023.
Source: Biospace
